Subscribe To
IMRA / Imara To Start Testing Tovinontrine In Heart Failure Patients
IMRA News
By Zacks Investment Research
May 19, 2022
What Makes IMARA Inc. (IMRA) a New Buy Stock
IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the more_horizontal
By Benzinga
April 5, 2022
Read Why Imara Shares Are Falling Today
Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (S more_horizontal
By Seeking Alpha
March 15, 2022
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript more_horizontal
By Benzinga
January 25, 2022
Imara To Start Testing Tovinontrine In Heart Failure Patients
The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved more_horizontal
By Benzinga
January 25, 2022
Imara To Start Testing Tovinontrine In Heart Failure Patients
The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved more_horizontal
By Benzinga
January 25, 2022
Imara To Start Testing Tovinontrine In Heart Failure Patients
The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved more_horizontal